Infectious diseases

My approach to infectious diseases has always been multi-disciplinary. There is a constant arms race between both host and pathogen. Infection changes the host response and the host response exerts changes on the pathogen. Approaching these problems from a single host or pathogen centric view limits the chance for complete understanding. Most of my published works have been in the interface between both the host and the pathogen. Joining Bio5 will allow me to join other scientist interested in multi-disciplinary answers to complex questions.

Dr. Vedantam’s research interests are broadly focused on pathogenic mechanisms leading to antibiotic-associated diarrhea, and include host-pathogen studies of the diarrheagenic agent Clostridium difficile. C. difficile infection is currently a leading healthcare-acquired disease in the USA, incurring over $3 billion in treatment and containment costs. Dr. Vedantam’s laboratory uses multiple genomic and proteomic approaches to study C. difficile pathogenesis, including, but not limited to, automated iTRAQ-based comparative proteomics, and genomic analyses. Her laboratory also offers hospital surveillance and typing services, and a genetic manipulation program for clostridial pathogens. These efforts have identified attractive targets for interventions aimed at eliminating C. difficile from the gut, and are a focus of translational research goals. Dr. Vedantam is also involved in multiple teaching efforts, and offers a highly popular, upper-division, laboratory-based course on bacterial pathogens. The strengths she brings to any research endeavor are based on her expertise in genetic, mechanistic and animal model studies. Keywords: Infectious Disease, healthcare-associated infections, bacterial pathogenesis

Roger L. Miesfeld, Ph.D., Professor and Co-Chair, Dept. of Chemistry & Biochemistry, College of Science, University of Arizona. Mosquitoes are human disease vectors that transmit pathogens through blood feeding. One of these disease vectors is the Aedes aegypti mosquito, which have rapidly expanded their habitat and are contributing annually to 500,000 cases of Dengue hemorrhagic fever. On an even greater scale, Anopheline mosquitoes account for 250 million cases of malaria/yr, with up to 1 million deaths annually. The most common adult insecticides used for mosquito control are pyrethroids, which inhibit evolutionarily conserved sodium channels in the mosquito nervous system. Although these compounds have proven to be effective, mosquito resistance is an increasing problem and there is a pressing need to develop the next generation of safe and effective agents. Since blood meal feeding creates a unique metabolic challenge as a result of the extremely high protein and iron content of blood, it is possible that interfering with blood meal metabolism could provide a novel control strategy for mosquito born diseases. Our long term goal is to identify small molecule inhibitors that block blood meal metabolism in vector mosquitoes, resulting in feeding-induced death of the adult female, or a significant reduction in egg viability, as a strategy to control vector mosquito populations in areas of high disease transmission.

Anita Koshy, MD is an Associate Professor in the Department of Neurology and the Department of Immunobiology, and an affiliate of the Clinical Translational Science Institute and the Evelyn F. McKnight Brain Institute. Clinically, Dr. Koshy is a recognized expert in the area of Infectious Diseases of the Nervous System, and has co-authored 4 chapters on this subject. Dr. Koshy’s lab focuses on understanding how a common human parasite, Toxoplasma gondii, is able to persist in the mammalian brain (including in up to 1/3 of the human population.) The goals of this work are to: 1) improve treatments for patients with symptomatic toxoplasmosis (there are no drugs to cure patients of Toxoplasma) and 2) use the co-evolution between the parasite and the mammalian CNS to better understand how immune responses in brain can be triggered and aborted. The latter research may have broad applicability to disorders of the brain in which the immune response is dysfunctional; these disorders include Multiple Sclerosis, traumatic brain injury, and neurodegenerative diseases such as Alzheimer’s disease. Keywords: Neuroscience, Infectious Disease, Parasitology

Our goal is to merge the fields of synthetic organic chemistry with virology. We develop new reactions (and re-appropriate old ones) to gain insight into how viruses infects new host cells. Additionally, we are working to develop new methods to probe protein-protein interactions through the use of small molecules.Viruses can rapidly evolve and new tools are required to meet this ever-changing threat. While vaccinations have tamed many historically deadly viral diseases, there are still rogue viruses for which no vaccination strategy is available. Dengue virus (DENV), the virus that is responsible for dengue fever, hemorrhagic fever, and shock syndrome, is one such pathogen. The WHO estimates that the mosquito-borne pathogen infects over 50 million people each year. With a rapid increase in severe, potentially fatal, disease forms, DENV poses a significant risk to the 2.5 billion people who live in DENV endemic regions.

Dr. Galgiani has focused his career on Arizona’s special problems with Valley Fever. His work has included studies of the impact of Valley Fever on the general population and on special groups such as organ transplant recipients and patients with AIDS. For 19 years, as part of the NIH-sponsored Mycoses Study Group, Dr. Galgiani has been the project director of a coccidioidomycosis clinical trials group. Through collaboration, this group has evaluated new therapies for Valley Fever more rapidly and with greater clarity than might otherwise have been possible by investigators working in isolation. Dr. Galgiani has also been involved with efforts to prevent Valley Fever through vaccination. His group discovered and patented a recombinant antigen which is the basis for a vaccine candidate suitable for further development and clinical trials. Most recently, he has become the project leader for developing a new drug, nikkomycin Z, for treating Valley Fever. With recent NIH and FDA grant awards, clinical trials with this drug were resumed in 2007. Dr. Galgiani is also Chief Medical Officer of Valley Fever Solutions, Inc, a start-up company founded to assist in the drug’s development. In 1996, the Arizona Board of Regents accepted Dr. Galgiani’s proposal to establish the Valley Fever Center for Excellence for the Arizona universities. Based at the University of Arizona, the Center is pledged to spread information about Valley Fever, help patients with the severest complications of this disease, and to encourage research into the biology and diseases of its etiologic agent. The Center maintains a website (www.VFCE.Arizona.edu) and answers inquiries from health care professionals located in Arizona, other parts of the United States, and even from other countries. The Valley Fever Corridor Project, begun in 2009, intends to facilitate communication among Arizona clinicians to also improve patient care. In 2011, The Valley Fever Center in Phoenix was announced as a partnership between St. Joseph’s Hospital and the UA College of Medicine in Phoenix. It began operation in June, 2012. Research is increasing into the environmental biology of the fungus within its desert soil habitat as well as how the fungus caused disease and the body’s immunity controls it. Since Arizona has the only medical schools situated directly within the endemic region for Valley Fever, it is quite appropriate that Arizona lead in solving this problem. As Director of the Center, Dr. Galgiani is working for its full implementation as a means of ensuring an institutional commitment to accomplish this goal. Keywords: Coccidioidomycosis, Valley Fever, antifungal drugs, vaccines, serologic tests,

Judith Brown, PhD, and her research interests include the molecular epidemiology of whitefly-transmitted geminiviruses (Begomoviruses, Family: Geminiviridae), the basis for virus-vector specificity and the transmission pathway, and the biotic and genetic variation between populations of the whitefly vector, B. tabaci, that influence the molecular epidemiology and evolution of begomoviruses. Keywords: Plant viral genomics, emergent virus phylodynamics, functional genomics of insect-pathogen interactions